Literature DB >> 9016768

Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production.

K Du1, P Nicole, A Couvineau, M Laburthe.   

Abstract

VIP receptors belong to a subfamily of G protein-coupled receptors that includes secretin, glucagon, PTH and several other receptors. We have used site-directed mutagenesis to investigate the requirement of some highly conserved residues in the extracellular loops including aspartate 196 (mutant D196A), leucine 199 (mutant L199A), tryptophane 286 (mutant W286A) and tryptophane 294 (mutant W294A) for the ability of the human VIP1 receptor to bind VIP and to mediate VIP-stimulated cAMP production. After transfection of mutated cDNAs in Cos-7 cells, it appeared that 1) mutants L199A, W286A and W294A bound VIP with the same dissociation constant as the wild-type receptor whereas mutant D196A did not bind 125I-VIP; 2) mutants L199A, W286A and W294A mediate VIP-stimulated cAMP production with the same EC50 as the wild-type receptor whereas VIP displayed a 500-fold decrease of potency in promoting cAMP production through mutant D196A. Since all mutated receptor proteins were expressed and delivered at the plasma membrane (immunofluorescence studies), it is concluded that the first extracellular loop of the human VIP1 receptor contains a highly conserved aspartate residue which is essential for VIP binding and VIP-stimulated cAMP production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9016768     DOI: 10.1006/bbrc.1996.5949

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors.

Authors:  E M Lutz; C J MacKenzie; M Johnson; K West; J A Morrow; A J Harmar; R Mitchell
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 2.  Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs.

Authors:  M Dong; C Koole; D Wootten; P M Sexton; L J Miller
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity.

Authors:  Quan Chen; Delia I Pinon; Laurence J Miller; Maoqing Dong
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

4.  Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.

Authors:  K Coopman; R Wallis; G Robb; A J H Brown; G F Wilkinson; D Timms; G B Willars
Journal:  Mol Endocrinol       Date:  2011-08-25

5.  Role of second extracellular loop in the function of human vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide receptor 1 (hVPAC1R).

Authors:  S M Knudsen; J W Tams; J Fahrenkrug
Journal:  J Mol Neurosci       Date:  2000-06       Impact factor: 3.444

6.  CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor.

Authors:  Georg Krainer; Mathias Schenkel; Andreas Hartmann; Dorna Ravamehr-Lake; Charles M Deber; Michael Schlierf
Journal:  J Biol Chem       Date:  2019-12-27       Impact factor: 5.157

7.  The VPAC1 receptor: structure and function of a class B GPCR prototype.

Authors:  A Couvineau; E Ceraudo; Y-V Tan; P Nicole; M Laburthe
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-16       Impact factor: 5.555

8.  Extracellular loops 1 and 3 and their associated transmembrane regions of the calcitonin receptor-like receptor are needed for CGRP receptor function.

Authors:  James Barwell; Alex Conner; David R Poyner
Journal:  Biochim Biophys Acta       Date:  2011-06-16

Review 9.  Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors.

Authors:  Kelly J Culhane; Yuting Liu; Yingying Cai; Elsa C Y Yan
Journal:  Front Pharmacol       Date:  2015-11-05       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.